Kiora Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
KPRX
CUSIP
49721T507
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 49721T507 since 12/18/2024, newest first.

Filer % of Class Filed
Baselake Partners, LP 13G
5.8% 9/17/2026
Event 9/10/2026
ADAR1 Capital Management, LLC 13G/A Amendment 2
9.9% 8/14/2026
Event 6/30/2026
Nantahala Capital Management, LLC 13G/A Amendment 3
10.0% 8/14/2026
Event 6/30/2026
Perceptive Advisors LLC 13G
10.0% 8/10/2026
Event 4/6/2026
Alyeska Investment Group, L.P. 13G
10.0% 5/15/2026
Event 3/31/2026
Nantahala Capital Management, LLC 13G/A Amendment 2
10.0% 5/15/2026
Event 3/31/2026
Nantahala Capital Partners Limited Partnership 13G/A Amendment 1 3.4% 5/15/2026
Event 3/31/2026
Perceptive Advisors LLC 13G
10.0% 4/13/2026
Event 4/6/2026
Orin Hirschman 13G/A Amendment 2
4.9% 1/29/2026
Event 12/31/2025
Nantahala Capital Management, LLC 13G/A Amendment 1
10.0% 11/14/2025
Event 9/30/2025
ADAR1 Capital Management, LLC 13G/A Amendment 1
9.9% 8/14/2025
Event 6/30/2025
Nantahala Capital Partners Limited Partnership 13G 5.3% 8/14/2025
Event 8/8/2025
Alyeska Investment Group, L.P. 13G/A Amendment 1
2.5% 2/14/2025
Event 12/31/2024
Goldman Sachs Group Inc 13G/A Amendment 1
0% 2/12/2025
Event 12/31/2024
Orin Hirschman 13G/A Amendment 1
8.5% 2/10/2025
Event 12/31/2024
Nantahala Capital Management, LLC 13G
10.0% 11/14/2024
Event 9/30/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q2 22 1.11 M $2.91 M
2026 Q1 18 339 k $655 k
2025 Q4 19 707 k $1.39 M
2025 Q3 17 616 k $1.71 M
2025 Q2 17 932 k $2.68 M
2025 Q1 19 1.29 M $3.87 M
2024 Q4 17 1.26 M $4.16 M
2024 Q3 19 1.21 M $4.44 M
2024 Q2 18 966 k $4.06 M